[Atherosclerosis and arteriitis: implications for therapy of cardiovascular disease].
D000804:Angiotensin II / Q000502:physiology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D001167:Arteritis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D002986:Clinical Trials as Topic; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D018384:Oxidative Stress / Q000502:physiology; D017382:Reactive Oxygen Species / Q000097:blood
D000806:Angiotensin-Converting Enzyme Inhibitors; D000893:Anti-Inflammatory Agents; D000924:Anticholesteremic Agents; D000975:Antioxidants; D018836:Inflammation Mediators; D008077:Lipoproteins, LDL; D017382:Reactive Oxygen Species; C099252:oxidized low density lipoprotein; D000804:Angiotensin II
Atherosklerose und ArteriitisDie inflammatorische Hypothese: Konsequenzen für die Therapie von kardiovaskulären Erkrankungen.